Patient reported side effects from molecularly targeted therapies in renal cell carcinoma

Conclusions:These results suggest that the patient-reported impact of molecularly targeted agent side effects may be more significant than suggested by phase III clinical trials. These results also identify specific side effects towards which improved symptom management strategies and enhanced patient education can be directed. Better side effect management may increase treatment duration and improve clinical outcomes.06/25/2010
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news